Status:
UNKNOWN
NAT2 in Re-challenge of INH in Patients With Hepatitis
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Department of Health, Executive Yuan, R.O.C. (Taiwan)
Conditions:
Tuberculosis
Hepatotoxicity
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Apply the information of NAT2 genotyping into the re-challenge protocol of INH titration in patients with anti-TB medication induced hepatitis.
Detailed Description
adjusting INH dose according to NAT2 genotyping and serum concentration of INH.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Older than 18 years-old
- Taken INH for more than 1 week
- Abnormal liver function
- Exclusion criteria:
- Rule out the INH induced liver abnormality
- Existing reasons to cause liver abnormality other than TB-medication
- Taking drugs which interact with INH
Exclusion
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2015
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00728546
Start Date
June 1 2008
End Date
November 1 2015
Last Update
December 27 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100